Keybanc analyst Kenneth Zener upgrades Toll Brothers (NYSE:TOL) from Underweight to Sector Weight.
XBiotech Shares Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment For Advanced Pancreatic Cancer
XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix